Halaven price in Italy likely to be higher than UK price rejected by NICE
This article was originally published in Scrip
Executive Summary
As Eisai considers how to respond to negative funding recommendations in England for Halaven, its end of life breast cancer drug, the company says it is not expecting such a bumpy ride elsewhere. Eventual approval from the Scottish Medicines Consortium looks likely, while reimbursement assessment is approaching in Italy, and at a better price than that offered in the UK, Nick Burgin, the company's European director of market access, told Scrip.